The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study
Open accessAbstract
Fatal hepatitis B virus (HBV) reactivation in lymphoma patients with “resolved” HBV infection (hepatitis B surface antigen [HBsAg] negative and hepatitis B core antibody [anti-HBc] positive) can occur, but the true incidence and severity remain unclear. From June 2009 to December 2011, 150 newly diagnosed lymphoma patients with resolved HBV infection who were to receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-based chemotherapy were prospectively followed. HBV DNA was checked at baseline, at the start of each cycle of chemotherapy, and every 4 weeks for 1 year after completion of rituximab-CHOP chemotherapy. Patients with documented HBV reactivation were treated with entecavir at a dosage of 0.5 mg/day for 48 weeks. HBV reactivation was defined as a greater than 10-fold increase in HBV DNA, compared with previous nadir levels, and hepatitis flare was defined as a greater than 3-fold increase in alanine aminotransferase (ALT) that exceeded 100 IU/L. Incidence of HBV reactivation and HBV-related hepatitis flares was 10.4 and 6.4 per 100 person-year, respectively. Severe HBV-related hepatitis (ALT >10-fold of upper limit of normal) occurred in 4 patients, despite entecavir treatment. Patients with hepatitis flare exhibited significantly higher incidence of reappearance of HBsAg after HBV reactivation (100% vs. 28.5%; P = 0.003). Conclusion: In lymphoma patients with resolved HBV infections, chemotherapy-induced HBV reactivation is not uncommon, but can be managed with regular monitoring of HBV DNA and prompt antiviral therapy. Serological breakthrough (i.e., reappearance of HBsAg) is the most important predictor of HBV-related hepatitis flare. (Hepatology 2014;59:2092–2100)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
EASL clinical practice guidelines management of chronic hepatitis B
张学武, & Li, X. (2009) · Inter J Epidemiol Infect Dis · doi:10.3760/cma.j.issn.1673-4149.2009.04.001 · Cited by 1,506
Yeo, W., Chan, T. C., Leung, N. W. Y., Lam, W. Y., Mo, F. K. F., Chu, M. T., Chan, H. L. Y., Hui, E. P., Lei, K. I. K., Mok, T. S. K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0182 · Cited by 636
Lau, G. K. K., Yiu, H. H. Y., Fong, D. Y. T., Cheng, H.-C., Au, W.-Y., Lai, L. S. F., Cheung, M., Zhang, H.-Y., Lie, A., Ngan, R., et al. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.026 · Cited by 458
Hui, C., Cheung, W. W. W., Zhang, H., Au, W., Yueng, Y., Leung, A. Y. H., Leung, N., Luk, J. M., Lie, A. K. W., Kwong, Y., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.04.015 · Cited by 453
Huang, Y.-H., Hsiao, L.-T., Hong, Y.-C., Chiou, T.-J., Yu, Y.-B., Gau, J.-P., Liu, C.-Y., Yang, M.-H., Tzeng, C.-H., Lee, P.-C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5938 · Cited by 326
Hsu, C., Hsiung, C. A., Su, I.-J., Hwang, W.-S., Wang, M.-C., Lin, S.-F., Lin, T.-H., Hsiao, H.-H., Young, J.-H., Chang, M.-C., et al. (2008) · Hepatology · doi:10.1002/hep.22106 · Cited by 305
Self-citationNew insight in the pathobiology of hepatitis B virus infection
Dandri, M., & Locarnini, S. (2012) · Gut · doi:10.1136/gutjnl-2012-302056 · Cited by 233
Does rituximab increase the incidence of infectious complications? A narrative review
Kelesidis, T., Daikos, G., Boumpas, D., & Tsiodras, S. (2011) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2010.03.025 · Cited by 221
Cited by
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Self-citationReddy, K. R., Beavers, K. L., Hammond, S. P., Lim, J. K., & Falck-Ytter, Y. T. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.039 · Cited by 861
Global burden of hepatitis B virus: current status, missed opportunities and a call for action
Hsu, Y.-C., Huang, D. Q., & Nguyen, M. H. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00760-9 · Cited by 632
Update of the statements on biology and clinical impact of occult hepatitis B virus infection
Raimondo, G., Locarnini, S., Pollicino, T., Levrero, M., Zoulim, F., Lok, A. S., Allain, J.-P., Berg, T., Bertoletti, A., Brunetto, M. R., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.034 · Cited by 572
Perrillo, R. P., Gish, R., & Falck-Ytter, Y. T. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.038 · Cited by 504
Metadata
- Authors
- Hsu, C., Tsou, H.-H., Lin, S.-J., Wang, M.-C., Yao, M., Hwang, W.-L., Kao, W.-Y., Chiu, C.-F., Lin, S.-F., Lin, J., Chang, C.-S., Tien, H.-F., Liu, T.-W., Chen, P.-J., & Cheng, A.-L.
- Venue
- Hepatology
- Published
- 2014-06
- Volume
- 59
- Issue
- 6
- Pages
- 2092-2100
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1979792611
- Cited by
- 277
- References
- 19
- FWCI
- 20.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. https://app.cochat.ai/papers/10.1002/hep.26718
- The paper
- Hsu, C., Tsou, H.-H., Lin, S.-J., Wang, M.-C., Yao, M., Hwang, W.-L., Kao, W.-Y., Chiu, C.-F., Lin, S.-F., Lin, J., Chang, C.-S., Tien, H.-F., Liu, T.-W., Chen, P.-J., & Cheng, A.-L. (2014). Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. Hepatology. https://doi.org/10.1002/hep.26718
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.